CALR-Mutated MPN: A Shared Neoantigen Makes Immunotherapy Possible, and Antibodies Lead So Far - Oncodaily
Oncodaily reviews the immunotherapy case for CALR-mutated essential thrombocythemia and primary myelofibrosis, where the type 1 (52-bp deletion) and type 2 (5-bp insertion) exon 9 variants both yield the same 36-amino-acid neomorphic C-terminal sequence absent from wild-type calreticulin. Because mutant CALR drives disease by binding and activating MPL independently of thrombopoietin, and mutant CALR-MPL complexes reach the cell surface, this shared driver neoantigen is targetable by vaccines, monoclonal and bispecific antibodies, and engineered T cells. For investors, the signal is a shared-antigen, off-the-shelf opportunity in a defined molecular MPN subgroup; per the piece, antibodies currently lead the field, with vaccines and cell therapies behind.